Studying Tocilizumab (study drug) in Patients With Severe COVID-19 Pneumonia

The purpose of this study is to evaluate the safety and effectiveness of the medication tocilizumab for adult patients with severe COVID-19 related pneumonia. 

This research study is led by Dr. Daniel Skiest.

Contact: Lori Kozikowski, 413-794-5584

Primary Sponsor: Hoffmann-La Roche

Participation details:

April 06, 2020
Infection, COVID19
Baystate Medical Center, 759 Chestnut Street, Springfield, MA
Hospitalized with COVID-19 pneumonia confirmed per WHO criteria (including a positive PCR of any specimen; e.g., respiratory, blood, urine, stool, other bodily fluid) and evidenced by chest X-ray or CT scan.
Total time in the study will be about 60 days.